Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2+ Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06650423
What this trial is testing

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

Who this might be right for
Early Breast CancerHormone Receptor Positive TumorHER2-negative Breast Cancer
Institute of Oncology Ljubljana 319
Large-scale testing (Phase 3)Ended earlyNCT00543127
What this trial is testing

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 870
Not applicableStudy completedNCT06619704
What this trial is testing

Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 194
Testing effectiveness (Phase 2)Study completedNCT03988036
What this trial is testing

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Who this might be right for
Breast Cancer
Women's Cancer Study Group GmbH 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT04293393
What this trial is testing

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Who this might be right for
Early Breast Cancer
Spanish Breast Cancer Research Group 200
Large-scale testing (Phase 3)Looking for participantsNCT06966700
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Who this might be right for
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC 2,400
Testing effectiveness (Phase 2)Study completedNCT07162051
What this trial is testing

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Xijing Hospital 28
Not applicableLooking for participantsNCT06797531
What this trial is testing

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

Who this might be right for
HR+/HER2- Early Breast Cancer
Novartis Pharmaceuticals 177
Testing effectiveness (Phase 2)Looking for participantsNCT06860529
What this trial is testing

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Breast Cancer
Henan Cancer Hospital 357
Testing effectiveness (Phase 2)Looking for participantsNCT07616453
What this trial is testing

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 45
Testing effectiveness (Phase 2)Looking for participantsNCT06970912
What this trial is testing

CtDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHigh-risk Breast CancerEarly-Stage Breast Cancer+3 more
Peking University People's Hospital 393
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07428018
What this trial is testing

Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib

Who this might be right for
Breast CancerHER2 + Breast CancerHR Positive+1 more
Mario Negri Institute for Pharmacological Research 150
Large-scale testing (Phase 3)Looking for participantsNCT07019363
What this trial is testing

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Who this might be right for
Breast CancerAdjuvant Therapy
Fudan University 1,903
Not applicableLooking for participantsNCT06185569
What this trial is testing

FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon 4,500
Large-scale testing (Phase 3)Active Not RecruitingNCT04055493
What this trial is testing

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Who this might be right for
Breast Cancer Female
Women's Cancer Study Group GmbH 1,684
Large-scale testing (Phase 3)Active Not RecruitingNCT03701334
What this trial is testing

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 5,101
Not applicableNot Yet RecruitingNCT06871501
What this trial is testing

"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Who this might be right for
Breast Cancer
Consorzio Oncotech 1,000
Not applicableLooking for participantsNCT05878314
What this trial is testing

Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
University Hospital Tuebingen 504
Not applicableLooking for participantsNCT07211178
What this trial is testing

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Who this might be right for
Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Tempus AI 900
Not applicableNot Yet RecruitingNCT07484763
What this trial is testing

Predicting Recurrence in HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer, HR+/HER2- Early-Stage
Shengjing Hospital 500
Next Page